Abstract:Background: The metabolic changes of malignant cells are earlier than these of morphology. F-18-fluorodeoxyglucose (FDG) single-photon emission computed tomography (SPECT)-computed tomography (CT) systems provide functional and anatomic images that could significantly improve its diagnostic capability. The molecular mechanisms of increased FDG uptake are still not fully understood. The correlation between FDG uptake and the expression of Glut in various tumor cells is still under debate. Further study is necessary to correlate increased FDG uptake by tumors with their Glut-1 and Glut-3 expression, which will lead to a better understanding and interpretation of SPECT-CT imaging. In this study, we, therefore, investigated in patients with head and neck carcinoma (HNC) the relationship between tumor FDG accumulation and the mRNA expression and protein expression of Glut-1 and Glut-3. Materials and Methods: Overall, 25 patients with HNC who underwent SPECT-CT imaging and CT or magnetic resonance imaging (MR1) studies were performed between April 2002 and March 2004. Then, the mRNA and protein expression of Glut-1 and Glut-3 in these 25 surgical or biopsied samples were studied with HNC to determine the correlate increased FDG uptake by tumors with their Glut-1 and Glut-3 expression. Results: Visual analysis of F-18-FDG SPECT-CT gave sensitivity, specificity, and accuracy levels of 100%, 62.5%, and 88%, respectively. The tumor-to-background (T/B) ratios were 94.1%, 87.5%, and 92.0% for F-18-FDG SPECT/CT, and 64.7%, 50.0%, and 60.0% for CT and MRI. This indicates that F-18-FDG SPECT-CT is superior to CT and MRI. Significant correlation was found between FDG and Glut-1 mRNA or Glut-1 protein (p < 0.001). There was no correlation between T/B ratio and Glut-3 mRNA (r = 0.14, p > 0.01). Conclusions: F-18-FDG SPECT-CT can be as a prospective toot that can judge the malignancy or benignity of head and neck tumor, stage and class h; the tumor, distinguish recurrence or necrosis or fibrosis of the tumor after treatment by surgery or radiotherapy, and detect unknown primary tumor. Glut-1 may largely mediate basal glucose transport in HNC cells.

Metabolic imaging in recurrent gliomas: comparative performance of 18F-FDOPA, 18F-fluorocholine and 18F-FDG PET/CT

[Value of 18F-FDG Metabolic Imaging in Diagnosis and Treatment of Head and Neck Tumors and Its Mechanism Study].

Clinical Significance of FDG Single-Photon Emission Computed Tomography: Computed Tomography in the Diagnosis of Head and Neck Cancers and Study of Its Mechanism.

Clinical Application of FDG PET for the Diagnosis of Recurrence in Glioma

Glucose Metabolic Profile by Visual Assessment Combined with Statistical Parametric Mapping Analysis in Pediatric Patients with Epilepsy.

Diagnostic value of PET with different radiotracers and MRI for recurrent glioma: a Bayesian network meta-analysis

Comparison of Cell Proliferation, Protein, and Glucose Metabolism in Musculoskeletal Tumors in a PET Study.

Comparing [18F]FET PET and [18F]FDOPA PET for glioma recurrence diagnosis: a systematic review and meta-analysis

Accuracy of 11C-choline positron emission tomography in differentiating glioma recurrence from radiation necrosis: A systematic review and meta-analysis.

Complex Diagnostic Challenges in Glioblastoma: The Role of 18F-FDOPA PET Imaging

The Study on the Application of Positron Emission Tomography in Preoperative Estimation and Neuronavigation-Assisted Operation of Brain Glioma.

Imaging glioma biology: spatial comparison of amino acid PET, amide proton transfer, and perfusion-weighted MRI in newly diagnosed gliomas

Comparative evaluation of 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography for distinguishing between primary central nervous system lymphoma and isocitrate dehydrogenase-wildtype glioblastoma

Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme: correlating sodium MRI and F-18 FLT PET on a voxel-wise basis

Accuracy of 18F-FDOPA Positron Emission Tomography and 18F-FET Positron Emission Tomography for Differentiating Radiation Necrosis from Brain Tumor Recurrence

Comparison of MRI, F-18 FDG, and 11C-choline PET/CT for their potentials in differentiating brain tumor recurrence from brain tumor necrosis following radiotherapy.

Recurrence Patterns after Radiotherapy for Glioblastoma with [(11)C]methionine Positron Emission Tomography-Guided Irradiation for Target Volume Optimization

Narrow interval dual phase 18F-FDG PET/CT: A practical approach for distinguishing tumor recurrence from radiation necrosis in brain metastasis

Comparative Analysis of Recurrent Glioblastoma Target Contours via 11C-Methionine, 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography, and Magnetic Resonance Imaging: Implications for Precision Radiotherapy Planning

FET PET to differentiate between post-treatment changes and recurrence in high-grade gliomas: a single center multidisciplinary clinic controlled study

Evaluating the Diagnostic Efficacy of 99mTc-Methionine Single-Photon Emission Computed Tomography–Computed Tomography: A Head-to-Head Comparison with 11C-Methionine Positron Emission Tomography–Magnetic Resonance Imaging in Glioma Patients